TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to maximum observed plasma concentration (Tmax) of venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleth Variability Index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dermal sensitization potential
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness rate for physician's evaluation of this product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma latanoprost acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success-rate and partial success-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The inhibitor recurrence (relapse) rate in the first twelve months after successful ITI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline oral health-related quality of life at one year
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in cognition as measured by the Mini Mental Status Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in cognition as measured by the Montreal Cognitive Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in cognition as measured by the Consortium to Establish a Registry in Alzheimer's disease Word List Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in cognition as measured by Letter and Category Fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in cognition as measured by the Boston Naming Test (Short Form)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with rehospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with mortality
Endpoint domain: Mortality/survival
Primary endpoint: Total Ephedrine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause Peri-operative Death at 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Index Limb Amputation Within 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Index Limb Re-intervention Within 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Index-limb-Related Death Within 1 Year Post Index Procedure
Endpoint domain: Mortality/survival
Primary endpoint: Primary Patency of the Target Lesion at 12 Month Post Index Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viral particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of patients with drug-related adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with positive vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of amelioration of at least 20% in ACR criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean latency to persistent sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications during post-operative care
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed analyte plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the analyte plasma concentration-time curve to the last quantifiable sampling time point (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macronutrient and micronutrient intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Brain-Derived Neurotrophic Factor (BDNF) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of Homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resting state intrinsic connectivity within the emotion processing network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment emergent serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cardiac function and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Scale for Suicide Ideation - Current (SSI-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS) Rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prostate position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute difference between RFR and FFR observed versus expected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved 6 minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hgb at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative incidence of grade 3+ toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Community Reintegration
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Frontal Systems Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lack of serious and severe adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: treatment feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized Modified Rankin Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: vHIT gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: paired semi-circular canal asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Peak Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGEs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dietary intake of AGEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of coronary artery plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delay Discounting Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pT0 Rate
Endpoint domain: Mortality/survival
Primary endpoint: ≤ pT1 Rate
Endpoint domain: Mortality/survival
Primary endpoint: max TBR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic management of calcium and phosphate abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline J-Tpeakc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline QTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTc Shortening From Calcium Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success in identification of nerve tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of missed pills
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Ferriscan® R2 Liver Iron Concentrations (LIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Cardiac T2* Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Therapeutic response according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of diarrhea without recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quadriceps Muscle Strength assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lower limb functional disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Perceptual Reasoning Index at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Perceptual Reasoning Index at 9 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: total propofol requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional treatment to complete abortion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sum score of common side effects of chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Safe Dose for Oral 5-ALA Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity, Specificity, and Positive Predictive Value of 5-ALA Mediated Fluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Signs and Symptoms of Acute Chest Syndrome or Duration of Hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve sensory and motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of steps taken by participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total distance traveled by participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time participant is active
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with care during pregnancy and postnatal period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients benefiting from early low-volume ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Weight gain and nutritional status in mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Checklist-20 (SCL-20)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of myopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical response in patients with epithelial ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Abundance of pathogen proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exclusive Breastfeeding Rate at Four Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients experiencing a bowel movement within 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Buprenorphine Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative bone fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of responders based on serum P levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Range of motion (ROM) during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor cells found in blood stream
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Appearance of complex regional pain syndrome (CRPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe grade 3 or 4 neurotoxicity or neuropathic pain
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Unified Parkinson's Disease Rating Scale (Parts II and III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Posttraumatic Growth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Physician Global Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physician Target Lesion Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute PDS Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGA-CHE Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Died During the Overall Study
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) as Median Time to Event During the Overall Study
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Event-Free (Alive) at 1 Year During the Overall Study
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability measured by number of subjects who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum plasma concentration (Cmax) of multiple oral doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time 0 to time of last measurable concentration (AUClast) of multiple oral doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of death, MI, repeat urgent revascularization, stroke
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerant dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of cASCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of cASCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palpebral fissure size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life in Adult Cancer Survivors (QLACS) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Swallowing function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With TEAEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With TEAEs Leading to Change in Dose or Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Time of weaning of IV vasopressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRC screening uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in use of safety behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Efficacy to Use Harm Reduction Strategies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider Behavior
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximal Measured Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3H cholesterol levels in plasma and lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients Who Complete 5 Cycles Without Progressive Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual relative change of abdominal visceral fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Loneliness as measured by UCLA Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Adolescent Drug Use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anatomical classified action of the Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Influenza vaccine coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline at Amygdala modulation ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Proportion of Patients With ACR20 at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 24 in mTSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine milligram equivalents (MME) administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Limb Event - free survival
Endpoint domain: Adverse events/effects
Primary endpoint: Restenosis
Endpoint domain: Adverse events/effects
Primary endpoint: Participants Completing CRC Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Death (CV death followed by non-CV death)
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalization due to heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Immediate and Post-discharge Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Sputum cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function: Spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung function: Oscillometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in I-PSS points after 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving I-PSS reduction by 4 or more points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental/decremental AUC0-240 of hepatic glycogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extravascular Lung Water Index (ELWI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: tissue changes in advanced hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraoperative fluid demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of eligible participants that agree to participate in the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: vomiting visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHOQOL-Brief questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lipid composition in tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid composition in whole breast tissue surrounding tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Water displacement in tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of early hospital-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in volume of index tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Estimated area under receiver operating characteristic (ROC) curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor response assessed by pathological examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in SpO2/FiO2 Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Phonation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent's acceptance of soy-based infant formula
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nerve fiber layer changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Macular changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scores on the Self-Compassion Scale (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores on the Pain Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning